A biotechnology startup called Paterna Biosciences has announced it successfully grew human sperm in a laboratory setting and used it to create embryos, claiming to have decoded the cellular instructions required to convert sperm-making stem cells into mature, functional sperm — a development that could eventually reshape treatment options for male infertility.
Paterna Biosciences, a startup working at the intersection of reproductive medicine and stem cell biology, says it has identified the precise set of molecular instructions needed to coax sperm-producing stem cells into becoming what the company describes as "normal, mature" sperm. The company further claims those lab-grown sperm were used to fertilise human eggs and produce embryos.
The announcement, reported by WIRED, represents one of the most significant claims in the field of in vitro spermatogenesis — the laboratory-based replication of the natural sperm-production process that occurs in the testes.
A long-sought goal in reproductive medicine
Scientists have spent decades attempting to replicate spermatogenesis outside the human body. The process is extraordinarily complex, requiring a precisely orchestrated sequence of genetic and biochemical signals. While researchers have previously achieved partial success in animal models — including mice — producing mature, fertilisation-capable human sperm from stem cells in a controlled laboratory environment has remained elusive.
If Paterna's claims are independently verified, the implications for male infertility treatment could be substantial. Infertility affects roughly one in six people globally, with male factors contributing to approximately half of all cases. For men who produce no sperm due to genetic conditions, cancer treatments, or other medical reasons, current options are extremely limited.
Significant caveats remain
As of publication, Paterna Biosciences had not released peer-reviewed data to support its claims. Independent reproductive scientists have not yet had the opportunity to scrutinise the company's methodology or results. In a field that has seen high-profile claims fail to hold up under scientific review, independent verification will be critical before the broader medical community accepts the findings.
The gap between producing embryos in a research setting and offering a viable, safe clinical fertility treatment is also considerable. Regulatory approval, long-term safety studies of any resulting pregnancies, and ethical review processes would all need to be navigated before the technique could be offered to patients.
The company has not publicly disclosed details about the source of the stem cells used, the efficiency of the sperm production process, or the developmental outcomes of the embryos created.
Analysis
Why This Matters
- If verified, this could open a new path to biological parenthood for men who are completely unable to produce sperm — a group with virtually no existing treatment options.
- The development sits at the crossroads of stem cell biology, reproductive medicine, and bioethics, raising important questions about the future of human reproduction and genetic parenthood.
- Commercial interest in the space could accelerate the science, but also introduces pressure to overstate results ahead of rigorous peer review.
Background
The scientific pursuit of lab-grown sperm has a history stretching back several decades. Researchers first demonstrated functional sperm could be produced from mouse stem cells around 2011, generating significant excitement. However, attempts to replicate this feat in humans have repeatedly stalled due to the far greater complexity of human spermatogenesis, which takes approximately 74 days and involves hundreds of distinct molecular signals.
Several research groups in Japan, China, the United States, and Europe have made incremental progress, producing sperm-like cells that resemble mature sperm but have generally lacked full motility or fertilisation capability. The field has also been dogged by replication failures and at least one high-profile retraction.
Parallel advances in induced pluripotent stem cell (iPSC) technology — which allows ordinary adult cells to be reprogrammed into stem cells — have renewed optimism that generating patient-specific sperm from skin or blood cells may eventually be possible.
Key Perspectives
Paterna Biosciences: The company positions its work as a potential solution for male infertility with no current treatment options, framing the identification of developmental instructions as a foundational scientific achievement.
Reproductive medicine specialists: Many in the field will welcome the announcement cautiously, noting that extraordinary claims require extraordinary evidence and that peer-reviewed publication with independent replication is the necessary next step before drawing firm conclusions.
Critics/Skeptics: Bioethicists and scientists familiar with the field's history will point to the absence of published data, the commercial incentives of a startup making pre-publication announcements, and the significant regulatory and safety hurdles that lie between embryo creation in a lab and a clinical fertility treatment.
What to Watch
- Whether Paterna Biosciences submits findings to a peer-reviewed journal and how quickly independent scientists can assess the methodology.
- Any regulatory filings or clinical trial applications that would signal the company is moving toward human trials.
- Responses from established academic fertility research centres, whose independent attempts to replicate the technique will be the true test of the claim's validity.